Last reviewed · How we verify
novel treatment
This novel treatment works by targeting a specific molecular pathway to produce a therapeutic effect.
This novel treatment works by targeting a specific molecular pathway to produce a therapeutic effect. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic non-small cell lung cancer, PD-L1 negative.
At a glance
| Generic name | novel treatment |
|---|---|
| Sponsor | Imperial College London |
| Drug class | Small molecule |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of action is complex and involves multiple steps, but it ultimately leads to a reduction in disease symptoms.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic non-small cell lung cancer, PD-L1 negative
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (PHASE1, PHASE2)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- Establishing of the Inter-rater Reliability and Variability of Selected Standardized Tests Performed in Czech Language
- The Effect of the DASH Diet on Treatment Outcomes in Adults Diagnosed With Rheumatoid Arthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- novel treatment CI brief — competitive landscape report
- novel treatment updates RSS · CI watch RSS
- Imperial College London portfolio CI